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Abstract 
Purpose: To investigate the antitumor and chemoresistance-lowering effects of pectolinarigenin on 
breast cancer cells. 
Methods: Pectolinarigenin was purified by a combination of silica gel and Sephadex LH-20 column 
chromatography from ethanol extracts of the aerial parts of C. japonicum DC. Breast cancer self-
renewal properties were tested by colony formation and tumor sphere formation assays. Thereafter, 
real-time polymerase chain reaction (PCR) was used to detect breast cancer stem cell markers. 
Furthermore, the effect of pectolinarigenin on breast cancer cell was evaluated by chemoresistance 
using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Finally, tumor 
formation in nude mice was used to test the effect of pectolinarigenin on tumorigenicity of breast cancer 
cells in vivo. 
Results: The results showed that pectolinarigenin, extracted from Cirsium japonicum Fisch. ex DC., 
inhibited tumor cell self-renewal in MCF-7 breast cancer cells. Pectolinarigenin (25 μM) caused 
significant inhibition of colony formation (61.23 %, p < 0.001) and tumor sphere formation (59.49 %, p < 
0.01) in MCF-7. The inhibitory effects were associated with changes in breast cancer stem cell markers. 
Treatment of breast cancer cells with pectolinarigenin reduced the chemoresistance of the cells to 
doxorubicin. At the same time, mRNA expression of chemoresistance genes (ATP binding cassette 
subfamily G member 2, ABCG2 and ATP binding cassette subfamily B member 1, MDR1) was 
repressed by pectolinarigenin. The inhibition efficiency of MDR1 and ABCG2 by 10 μM pectolinarigenin 
treatment was about 59.29 (p < 0.01) and 46.48 % (p < 0.01), respectively. Furthermore, 
pectolinarigenin reduced tumor mass in nude mice xenograft model. 
Conclusion: Pectolinarigenin inhibits breast cancer stem cell-like properties and lowers the 
chemoresistance of the cancer cells to chemotherapy. The results provide an insight into the 
mechanism of the anti-breast tumor effects and an experimental basis for the use of pectolinarigenin to 
enhance treatment of patients with breast cancer. 
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Breast cancer accounts for 22.9 % of all cancers 
(excluding non-melanoma skin cancers) in 
women worldwide [1]. The death rate caused by 
breast cancer is 13.7 % of cancer deaths in 
women in 2008 [1]. However, survival rates are 
much poorer in developing countries compared 
with the western world. Recrudesce of breast 
cancer is still a great threat to the treatment of 
breast cancer [2]. 
 
Cancer stem cell (CSCs) hypothesis suggests 
that, they are rare, tumor-initiating cells that 
exhibit stem cell properties: capacity of self-
renewal, pluripotency, highly tumorigenic 
potential, and resistant to therapy [2]. Cancer 
stem cells have been characterized and isolated 
from many cancers, including breast cancer. 
Cancer stem cells share many mechanisms 
described for tissue-specific stem cells, but due 
to oncogenic deregulations these cells have 
evolved even drug-intoxicating and antioxidant 
systems that may contribute to tumor recurrence 
and enhanced resistance to chemo- and/or 
radiotherapy. Thus, drugs that inhibit breast 
cancer cell self-renewal and reduce 
chemoresistance offer great promise for breast 
cancer treatment [3].  
 
Considerable efforts have been made to search 
for specific surface and intracellular biomarker in 
recent years. CD44+, CD24−/low, and ESA+ 
(epithelial specific antigen) and lacking 
expression of specific lineage 
(ESA+CD44+CD24−/low Lin−) have been 
identified as breast cancer stem cell markers [4]. 
Interestingly, accumulating evidence indicates 
that the expression of Oct3/4, Nanog, and Sox2 
transcription factors have a strong correlation 
with CSCs; knockdown of these genes inhibited 
tumor sphere formation and decreased tumor 
formation in xenograft tumor models [5,6]. 
 
Cirsium japonicum belongs to the family of 
Compositae and is widely used in traditional 
Chinese medicine (TCM) for the treatment of 
haemorrhage, hepatitis, hypertension and blood 
circulation [7]. Pharmacological studies show that 
the extract of C. japonicum and its major 
flavonoid constituents possess anti-tumor activity 
[7,8] 
 
Pectolinarigenin is a hydrophobic agent widely 
distributed in a number of fruits, vegetables and 
plants with potential anticancer activity. 
Pectolinarigenin has been shown to have an 
antioxidant activity, anti-inflammatory function 
and anti-aging properties [9,10].  
 
Recently, we have confirmed that 
pectolinarigenin showed potent anti-proliferation 
activity by inducing apoptosis and 
downregulation of Bcl2 expression in MCF-7 
breast cancer cell [11]. However, the effects of 
pectolinarigenin on breast cancer stem cell 
properties have rarely been investigated.  
 
Therefore, the aim of this study was to 
investigate the effect and mechanism of action of 





Plant material and equipment 
 
The aerial parts of C. japonicum were purchased 
from the market of Chinese herbal medicine in 
Zhang Shu (Jiang Xi, China) in July 2010 and 
authenticated by Qingzhi Kong (a senior 
taxonomist at Hubei University of Chinese 
Medicine). A voucher specimen (2010-07) has 
been deposited in the Hubei University of 
Chinese Medicine. 1H-and 13C-NMR spectra 
were recorded on a Bruker Avance-400 FT-NMR 
spectrometer, with TMS internal standard. ESI-
MS were recorded on 3200 Q-trap ESI-MS 
spectrometer (ABI, American). Column 
chromatography was performed with silica gel 
(200-300 mesh) and Sephadex LH-20 
(Pharmacia Co.). All the organic solvents used 
were of analytical grade and purchased from 
Sinopharm Chemical Reagent Co., Ltd 
(Shanghai, China).  
 
Extraction and isolation  
 
The extraction and isolation procedures had 
been reported previously [11]. Namely, the 
powdered air-dried aerial parts of C. japonicum 
(1 kg) were extracted three times with 6 L 80 % 
ethanol/10 % HCl (4:1, v/v) in a conical flask and 
refluxed at 80 °C for 2 h. The solvent was 
evaporated in vacuum and then the concentrated 
extract was partitioned with chloroform. The 
chloroform fraction was successively purified on 
silica gel (200-300 mesh) with CHCl3-MeOH 
gradient and on Sephadex LH-20 with CHCl3-




Human breast cancer cell line, MCF-7, was 
purchased from Institute of Cell Biology 
(Shanghai, China, http://www.cellbank.org.cn). 
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Cells were maintained in Dulbecco's modified 
eagle medium (DMEM). All cell culture media 
were supplemented with 10 % fetal bovine serum 
(FBS), and 1 % of penicillin-streptomycin (all 
from Invitrogen (Carlsbad, CA, http://www.invitro 
gen.com).  
 
Soft agar colony formation assay 
 
Triplicate samples of MCF-7 (1 × 103) were 
resuspended in 1 mL of DMEM containing 0.3 % 
low-melt agarose, 10 % fetal bovine serum, 1 % 
of penicillin-streptomycin. The cell mixture was 
plated on top of solidified layer with the same 
DMEM containing 0.6 % low-met agarose. Plates 
were incubated for 3 weeks at 37 oC in 5 % CO2 
in humidified incubator. Colony formation was 





Tumorspere cultures were made in ultralow 
attachment six-well plate (Corning, Lowell, MA, 
USA) in suspension (500 cells/mL) in serum-free 
DMEM/F12 media, supplemented with B27 (1:50, 
Invitrogen, Carlsbad, CA, USA), 20 ng/mL 
human recombinant epidermal growth factor 
(Sigma-Aldrich), 20 ng/mL basic fibroblast growth 
factor (Sigma-Aldrich), 4 μg/mL heparin (Sigma-
Aldrich), 5 μg/mL insulin (Sigma-Aldrich) and 1 % 
of penicillin-streptomycin in a humidified 
incubator at 37 oC in 5 % CO2 [12,13]. 
Tumorsphere formation was tested by culturing 
MCF-7 cells in the presence or absence of 
pectolinarigenin under the conditions mentioned 
above. 
 
RNA extraction, RT-PCR and quantitative 
real-time PCR 
 
Total RNA was extracted using TRIZOL Reagent 
(Invitrogen) and reverse transcribed with R-PCR 
Quick Master Mix (Toyoba) to produce cDNA. 
The primer sequences listed in Table 1 were 
used for quantitative real-time PCR. Real-time 
PCR was performed using SYBR Green-based 
detection in LightCycler○R480 (Roche) according 
to the manufacturer’s instructions. GAPDH 
(glyceraldehyde-3' phosphate dehydrogenase) 




The MTT assay (Cell titer 96○R Aqueous One 
Solution Cell Proliferation Assay, Promega) was 
used to assess the rates of resistance to drugs. 
Briefly, breast cancer cells (2 × 103/well) were 
seeded in 96-well plates. After 24 h in presence 
or absence of pectolinarigenin, the indicated 
concentration of doxorubicin (Ferrer Farma) was 
added and 72 h later, the MTT assay was 
performed using iMarkmicroplate Absorbance 
Reader (Bio-RAD, Richmond, CA) according to 
the manufacturer’s instructions. 
 





























































Tumor growth in xenografts 
 
MCF-7 Cells (5 × 106) were injected 
subcutaneously in the right flank of each of 8 
female 6-week old nude mice (Laboratory Animal 
Center, Xiamen University). All animals were 
maintained under controlled temperature, 
humidity, and 12 h light/dark cycles in the 
Xiamen University Laboratory Animal Center. 
The animals were fed standard rodent chow and 
allowed free access to water ad libitum. All 
experiments were carried out in accordance with 
NIH Guidelines for the Care and Use of 
Laboratory. Animal care and use was approved 
by the Ethics Committee of Faculty of Medicine-
Xiamen University-China. When the tumors 
developed at 7 days, the mice were randomly 
distributed into two groups, of untreated or  
treated by i.p. injection every day with 
pectolinarigenin (20 mg/kg). Tumor volume (Tv) 
was measured every 3 days and calculated as in 
Eq 1. 
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Tv = (LW2)/2 ………………………….. (1) 
 





The results are expressed as mean ± SEM. 
Statistical significance was determined by 
Student’s t-test or one-way or two-way analysis 
of variance (ANOVA) followed by Turkey’s test, 
as appropriate, using Graphpad Prism statistics 
software (Graphpad Software). p < 0.05 was 
considered statistically significant (*p < 0.05, **p 




Pectolinarigenin inhibited BCSCs self-
renewal properties  
 
The isolated compound was identified by a 
combination of NMR and mass spectral data as 
reported previously [11]. Soft agar colony 
formation assay and tumor sphere assay have 
been widely used to identity stem cells in in vitro 
assays. The colony formation capacity in MCF-7 
was firstly assayed under the treatment of 
pectolinarigenin. The results showed 
pectolinarigenin inhibited the colony formation 
capacity in MCF-7 cells in a dose dependent 
manner as shown in Fig 1A. Even 25 μM 
concentration of pectolinarigenin could cause 
significant inhibition of colony formation in MCF-7 
(61.23 %, p < 0.001, Fig 1A).  
 
Then the tumor sphere formation capacity was 
examined in MCF-7 under the treatment of 
pectolinarigenin. Tumor spheres of MCF-7 were 
cultured as described elsewhere [12]. Tumor 
spheres with a tight appearance were observed 
in serum free medium (Fig 1B). Those results 
showed that the breast cancer cells sphere 
formation capacity was inhibited by 
pectolinarigenin in a dose dependent manner as 
shown in Fig 1C, the inhibition efficiency of tumor 
sphere formation is 59.49 % when treated with 
25 μM pectolinarigenin (p < 0.01, Fig 1C). 
 
Moreover, BCSCs marker expression in 
monolayer MCF-7 cells, MCF-7 spheres and 
MCF-7 spheres treated with 25 μM 
pectolinarigenin were compared by real-time 
PCR. The results showed that the spheres 
expressed much higher levels of BCSCs 
markers, such as OCT-4, Sox2, Nanog, CD44, 
than the monolayer cells. At the same time, the 
spheres expressed much lower levels of CD24 
than the monolayer cells. The induction and 
repression of BCSCs markers were greatly 
reversed in the spheres treated with 25 μM 
pectolinarigenin compared with the untreated 
spheres (Fig 1D). 
 
Pectolinarigenin reduced breast cancer cell 
chemoresistance 
 
Studies in the past have suggested that 
chemoresistance is another characteristic of 
CSCs. Next studies were carried out to 
investigate whether pectolinarigenin would 
influence the chemoresistance of MCF-7 cells. 
For this purpose, MCF-7 cells were pre-treated 
with or without pectolinarigenin (10 μM) for 24 h 
and then 0.25 μM Doxorubicin was used to treat 
the cells. As showed in Fig. 2A, pectolinarigenin 
enhanced chemosensitivity to Doxorubicin. 
Moreover, we detected chemoresistant genes 
(MDR-1 and ABCG2) expression in MCF-7 when 
treated with pectolinarigenin (10 μM). As shown 
in Fig. 2B, MDR1 and ABCG2 expression were 
repressed under treatment with pectolinarigenin 
(10 μM). Especially, the inhibition efficiency of 
MDR1 and ABCG2 were about 59.29 % (p < 
0.01, Fig. 2B) and 46.48 % (p < 0.01, Fig. 2B) 
when treated with pectolinarigenin as compared 
with the control, respectively. 
 
Pectolinarigenin reduced tumorigenicity in 
vivo 
 
It has been reported that tumorigenicity in vivo 
correlates with the sphere formation ability of 
tumor cells in vitro. To test the effect of 
pectolinarigenin on the tumorigenicity of breast 
cancer cells, MCF-7 cells (5 × 106) were 
inoculated into nude BALB/C mice. When the 
tumors developed in 7 days, the mice were 
randomly distributed into two groups, of 
untreated or treated with pectolinarigenin (20 
mg/kg). The size and weight of xenograft tumors 
treated with pectolinarigenin were significantly 
smaller than control tumors (Fig. 3). These 
results thus demonstrated that pectolinarigenin 
efficiently attenuated the tumorigenicity of breast 




It is urgently required to develop an effective 
method of treatment of breast cancer, due to its 
high incidence and high recurrence rates in 
recent years. Hypothesis of cancer stem cells 
suggested that CSCs is the mainly responsible 
for causing relapse in cancer patients [2]. Bio-
flavonoids extracted from fruits and vegetables 
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have a variety of biological properties, including 
antibacterial, antioxidant, anti-inflammatory, 
antiviral, anticancer, cancer preventing activities 
[14,15]. Previously we have already 
demonstrated that the flavonoid pectolinarigenin 
inhibits the proliferation of breast cancer cell [11]. 
We speculated that inhibiting CSCs properties 
may be a potential mechanism of preventing 
carcinogenesis by pectolinarigenin. The tumor 
sphere assay has been used to identity breast 
cancer stem cells, as shown in Fig. 1D, CSCs 
markers (OCT4, Nanog, SOX2 and CD44) were 
greatly induced in our experimental system. The 
results demonstrated that pectolinarigenin 
inhibited breast cancer cell self-renewal capacity 
Consistent with the inhibitory effects, 
pectolinarigenin suppressed induction of BCSCs 
markers. 




Figure 1: Pectolinarigenin inhibited BCSCs self-renewal properties and negatively correlated with BCSCs 
characteristics. (A) Pectolinarigenin inhibited the colony formation capacity in MCF-7 in a dose-dependent 
manner. MCF-7 cells treated with the indicated concentrations of pectolinarigenin were plated in 0.3 % agrose, 
and colonies were counted 3 weeks later. Representative photograph of colony was shown on the top. Statistical 
analysis was shown on the bottom. (B) Representative photograph of tumor sphere. MCF-7 cells were cultured in 
the stem cell medium as described in the materials and methods.  (C) Pectolinarigenin inhibited the tumor sphere 
formation capacity in MCF-7 in a dose-dependent manner. MCF-7 cells treated with the indicated concentration 
of pectolinarigenin were cultured in the stem cell medium as described in materials and methods. (D) Several 
breast cancer stem cell markers expression in tumor spheres and monolayer cells. OCT-4, Nanog, Sox2, CD44, 
and CD24 expression in monolayer MCF-7 cells, MCF-7 spheres and MCF-7 spheres treated with 25 μM 
pectolinarigenin were detected by Real-Time PCR. Data are the mean ± SEM of three independent experiments. 
* p < 0.05, ** p < 0.01, *** p < 0.001 vs. control 
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Figure 2: Pectolinarigenin reduced breast cancer cell chemoresistance. (A) Pectolinarigenin reduced MCF-7 
chemoresistance. MCF-7 cells were pre-treated with or without pectolinarigenin (10 μM) for 24 h, and then 0.25 
μM Doxorubicin was added to the MCF-7 cells. Cell viability was determined by MTT assay. (B) Drug resistant 
genes expression in MCF-7 when treated with pectolinarigenin. MDR1 and ABCG2 expression in MCF-7 cells 
treated with 10 μM pectolinarigenin were detected by Real-Time PCR. Data are the mean ± SEM of three 
independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control 
 
    
 
Figure 3: Pectolinarigenin reduced tumorigenicity in 
vivo. (A) Tumors produced by MCF-7. MCF-7 Cell (5 × 
106) were injected subcutaneously in the right flank of 
nude mice (n=4). When the tumors developed in 7 
days, the mice were randomly distributed into two 
groups, and were untreated or treated by i.p. injections 
every day with pectolinarigenin (20 mg/kg). (B) Tumor 
growth curves were monitored every 3 days during the 
experimental period (n = 4).  Data represented the 
mean ± SEM of three independent experiments. * p < 
0.05, ** p < 0.01 vs. control 
 
Another characteristic of CSCs is 
chemoresistance. MDR1 and ABCG2 play an 
important role in chemoresistance of breast 
cancer cells [15]. Our results showed that 
pectolinarigenin enhanced breast cancer cell 
chemosensitivity to doxorubicin. The 
chemosensitivity is associated with 
downregulation of MDR1 and ABCG2 (Fig. 2B). 
Pectolinarigenin inhibited MDA1 and ABCG2 
mRNA expression, and at the same time, 
repressed tumor sphere formation. Our results 
are consistent with other reports that MDR1 and 
ABCG2 not only play a major role in multidrug 





The findings of this study indicate that 
pectolinarigenin inhibits BCSCs properties in 
vitro, reduces breast cancer cell tumorigenicity in 
vivo, and provides an experimental basis for the 
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